Does the media refer more to VKTX or MDGL?

In the previous week, Viking Therapeutics had 33 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 42 mentions for Viking Therapeutics and 9 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.47 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 16 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LLY or VKTX?

In the previous week, Eli Lilly and Company had 63 more articles in the media than Viking Therapeutics. MarketBeat recorded 105 mentions for Eli Lilly and Company and 42 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.52 beat Viking Therapeutics' score of 0.47 indicating that Eli Lilly and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eli Lilly and Company 42 Very Positive mention(s) 21 Positive mention(s) 25 Neutral mention(s) 12 Negative mention(s) 4 Very Negative mention(s) Positive Viking Therapeutics 16 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PFE or VKTX?

In the previous week, Viking Therapeutics had 4 more articles in the media than Pfizer. MarketBeat recorded 42 mentions for Viking Therapeutics and 38 mentions for Pfizer. Viking Therapeutics' average media sentiment score of 0.47 beat Pfizer's score of 0.41 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 16 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Viking Therapeutics 16 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, VKTX or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is VKTX or SMMT more profitable?

Viking Therapeutics' return on equity of -94.56% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Summit Therapeutics N/A -168.94% -141.92%

Does the media prefer VKTX or SMMT?

In the previous week, Viking Therapeutics had 25 more articles in the media than Summit Therapeutics. MarketBeat recorded 42 mentions for Viking Therapeutics and 17 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.56 beat Viking Therapeutics' score of 0.47 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 16 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor VKTX or BBIO?

In the previous week, Viking Therapeutics had 36 more articles in the media than BridgeBio Pharma. MarketBeat recorded 42 mentions for Viking Therapeutics and 6 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.73 beat Viking Therapeutics' score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 16 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viking Therapeutics (VKTX) Competitors

$32.82 +1.01 (+3.16%)

As of 03:49 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, SMMT, and BBIO

Should you buy Viking Therapeutics stock or one of its competitors? Viking Therapeutics's main competitors and comparable companies include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), Summit Therapeutics (SMMT), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Viking Therapeutics presently has a consensus price target of $99.67, indicating a potential upside of 203.71%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 40.96%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Viking Therapeutics had 33 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 42 mentions for Viking Therapeutics and 9 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.47 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	16 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Madrigal Pharmaceuticals	$1.28B	9.07	-$288.28M	-$12.89	N/A

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

Summary

Madrigal Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Eli Lilly and Company presently has a consensus target price of $1,311.96, indicating a potential upside of 13.31%. Viking Therapeutics has a consensus target price of $99.67, indicating a potential upside of 203.71%. Given Viking Therapeutics' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	3 Hold rating(s)	25 Buy rating(s)	1 Strong Buy rating(s)	2.87
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	16.72	$20.64B	$29.80	38.85
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Eli Lilly and Company has a net margin of 33.53% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 97.83% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	33.53%	97.83%	23.23%
Viking Therapeutics	N/A	-94.56%	-82.75%

Eli Lilly and Company has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

In the previous week, Eli Lilly and Company had 63 more articles in the media than Viking Therapeutics. MarketBeat recorded 105 mentions for Eli Lilly and Company and 42 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.52 beat Viking Therapeutics' score of 0.47 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	42 Very Positive mention(s)	21 Positive mention(s)	25 Neutral mention(s)	12 Negative mention(s)	4 Very Negative mention(s)	Positive
Viking Therapeutics	16 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Pfizer (NYSE:PFE) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Viking Therapeutics had 4 more articles in the media than Pfizer. MarketBeat recorded 42 mentions for Viking Therapeutics and 38 mentions for Pfizer. Viking Therapeutics' average media sentiment score of 0.47 beat Pfizer's score of 0.41 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	16 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Viking Therapeutics	16 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.70B	2.56	$7.77B	$0.76	37.57
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pfizer presently has a consensus target price of $28.39, suggesting a potential downside of 0.57%. Viking Therapeutics has a consensus target price of $99.67, suggesting a potential upside of 203.71%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Pfizer has a net margin of 6.80% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.63% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Viking Therapeutics	N/A	-94.56%	-82.75%

Pfizer has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Viking Therapeutics beats Pfizer on 8 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Summit Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Summit Therapeutics is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Viking Therapeutics' return on equity of -94.56% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Viking Therapeutics had 25 more articles in the media than Summit Therapeutics. MarketBeat recorded 42 mentions for Viking Therapeutics and 17 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.56 beat Viking Therapeutics' score of 0.47 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	16 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market.

Viking Therapeutics presently has a consensus target price of $99.67, indicating a potential upside of 203.71%. Summit Therapeutics has a consensus target price of $28.45, indicating a potential upside of 66.33%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Viking Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Viking Therapeutics beats Summit Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Viking Therapeutics compare to BridgeBio Pharma?

Viking Therapeutics (NASDAQ:VKTX) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, Viking Therapeutics had 36 more articles in the media than BridgeBio Pharma. MarketBeat recorded 42 mentions for Viking Therapeutics and 6 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.73 beat Viking Therapeutics' score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	16 Very Positive mention(s)	5 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
BridgeBio Pharma	$713.07M	18.12	-$724.93M	-$3.57	N/A

Viking Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Viking Therapeutics currently has a consensus target price of $99.67, suggesting a potential upside of 203.71%. BridgeBio Pharma has a consensus target price of $102.61, suggesting a potential upside of 55.24%. Given Viking Therapeutics' higher possible upside, equities analysts clearly believe Viking Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.84B	$3.95B	$7.23B	$13.13B
Dividend Yield	N/A	3.63%	2.52%	14.19%
P/E Ratio	-7.06	13.44	274.07	25.74
Price / Sales	N/A	1,416.75	660.31	97.80
Price / Cash	N/A	121.91	80.06	52.35
Price / Book	5.81	15.22	10.39	6.33
Net Income	-$359.64M	-$22.71M	$3.50B	$360.42M
7 Day Performance	-21.21%	-1.72%	-1.51%	-1.61%
1 Month Performance	2.04%	-8.14%	-4.37%	-4.11%
1 Year Performance	24.87%	26.78%	12.55%	3.82%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	2.9829 of 5 stars	$32.82 +3.2%	$99.67 +203.7%	+23.2%	$3.84B	N/A	N/A	65
MDGL Madrigal Pharmaceuticals	3.1704 of 5 stars	$529.09 +1.1%	$699.64 +32.2%	+15.0%	$12.09B	$958.40M	N/A	915
LLY Eli Lilly and Company	4.6839 of 5 stars	$1,138.66 +0.2%	$1,304.86 +14.6%	+63.3%	$1.07T	$65.18B	38.21	50,000	Trending News Analyst Forecast
PFE Pfizer	2.6586 of 5 stars	$27.48 -0.3%	$28.39 +3.3%	+20.4%	$157.03B	$62.58B	36.15	75,000	Trending News
SMMT Summit Therapeutics	2.8673 of 5 stars	$17.30 -0.6%	$25.91 +49.8%	-22.5%	$13.88B	N/A	N/A	265	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, SMMT, and BBIO

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to Summit Therapeutics?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, SMMT, and BBIO

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Do analysts prefer VKTX or MDGL?

Does the media refer more to VKTX or MDGL?

Which has stronger valuation & earnings, VKTX or MDGL?

Is VKTX or MDGL more profitable?

Do insiders & institutionals hold more shares of VKTX or MDGL?

Which has more volatility and risk, VKTX or MDGL?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Do analysts rate LLY or VKTX?

Which has higher valuation and earnings, LLY or VKTX?

Is LLY or VKTX more profitable?

Which has more risk and volatility, LLY or VKTX?

Does the media prefer LLY or VKTX?

Do insiders & institutionals hold more shares of LLY or VKTX?

Summary

How does Viking Therapeutics compare to Pfizer?

Does the media prefer PFE or VKTX?

Which has higher earnings & valuation, PFE or VKTX?

Do insiders & institutionals hold more shares of PFE or VKTX?

Do analysts recommend PFE or VKTX?

Is PFE or VKTX more profitable?

Which has more volatility & risk, PFE or VKTX?

Summary

How does Viking Therapeutics compare to Summit Therapeutics?

Which has higher valuation & earnings, VKTX or SMMT?

Is VKTX or SMMT more profitable?

Does the media prefer VKTX or SMMT?

Which has more volatility and risk, VKTX or SMMT?

Do analysts recommend VKTX or SMMT?

Do institutionals & insiders hold more shares of VKTX or SMMT?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Do institutionals and insiders hold more shares of VKTX or BBIO?

Which has more risk & volatility, VKTX or BBIO?

Does the media favor VKTX or BBIO?

Which has higher earnings & valuation, VKTX or BBIO?

Is VKTX or BBIO more profitable?

Do analysts prefer VKTX or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools